^
Association details:
| Biomarker: | CDKN2A mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
Published date:
09/17/2021
Excerpt:
In addition, the mutation frequency of multiple genes changed remarkably between the OS >12 months cohort and the OS ≤12 months cohort in the metastatic sample cohort. The top five upregulated genes (AZACN: ARID1A, ZFHX3, ATM, CDKN2A, and NTRK3) and the bottom two downregulated genes (BRAF and PIK3CA) were selected as combined predictors for screening responders from non-responders. The results suggested that patients harboring AZACN(+) received more OS benefits from immunotherapy than those harboring AZACN(−) or harboring BRAF and PIK3CA (+)...
DOI:
https://doi.org/10.3389/fimmu.2021.732125
Test:
